BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cantor Fitzgerald
QuintilesIMS
Dow
Novartis
US Department of Justice
Federal Trade Commission
Medtronic
UBS
Cipla

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,863,331

« Back to Dashboard

Summary for Patent: 7,863,331
Title:Pharmaceutical composition containing fenofibrate and method for the preparation thereof
Abstract:Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.
Inventor(s): Criere; Bruno (Gravigny, FR), Suplie; Pascal (Montaure, FR), Chenevier; Philippe (Montreal, CA), Oury; Pascal (Le Chesnay, FR), Rotenberg; Keith S. (Denville, NJ), Bobotas; George (Tarpon Springs, FL)
Assignee: Ethypharm (Saint Cloud, FR)
Application Number:10/677,861
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 7,863,331

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT ➤ Subscribe
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT ➤ Subscribe
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT ➤ Subscribe
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,863,331

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France99 08923Jul 09, 1999

Non-Orange Book US Patents Family Members for Patent 7,863,331

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,101,574 Pharmaceutical composition containing fenofibrate and the preparation method ➤ Subscribe
8,529,952 Pharmaceutical composition containing fenofibrate and method for the preparation thereof ➤ Subscribe
8,658,212 Pharmaceutical composition containing fenofibrate and method for the preparation thereof ➤ Subscribe
8,563,042 Pharmaceutical composition containing fenofibrate and method for the preparation thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,863,331

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia 50035 ➤ Subscribe
Yugoslavia 93201 ➤ Subscribe
Portugal 1667666 ➤ Subscribe
Portugal 1574214 ➤ Subscribe
Portugal 1523983 ➤ Subscribe
Portugal 1194140 ➤ Subscribe
Poland 212082 ➤ Subscribe
Poland 352307 ➤ Subscribe
New Zealand 546692 ➤ Subscribe
New Zealand 516416 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Farmers Insurance
Citi
Covington
UBS
Dow
Healthtrust
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot